Evidence map›Paper›PMID 39630579›Full record

ArticleCell reports2024

Biased signaling by mutant EGFR underlies dependence on PKCα in lung adenocarcinoma.

Mojtaba Sadeghi, Mohamed F Salama, Sam B Chiappone, Amy Huang, Andrew E Resnick, Manoj Kandpal, Christopher J Clarke, John D Haley, Ramana V Davuluri, Yusuf A Hannun

Abstract read
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mojtaba SadeghiDepartment of Biochemistry, Stony Brook University, Stony Brook, NY 11794, USA; Stony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY 11794, USA.
Mohamed F SalamaStony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY 11794, USA; Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Department of Biochemistry, Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Egypt.
Sam B ChiapponeStony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY 11794, USA.
Amy HuangStony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY 11794, USA.
Andrew E ResnickStony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY 11794, USA; Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11794, USA.
Manoj KandpalCentre for Clinical and Translational Science, Rockefeller University, New York, NY 10065, USA.
Christopher J ClarkeStony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY 11794, USA; Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
John D HaleyStony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY 11794, USA; Department of Pathology, Stony Brook University, Stony Brook, NY 11794, USA.
Ramana V DavuluriStony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY 11794, USA; Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY 11794, USA.
Yusuf A HannunDepartment of Biochemistry, Stony Brook University, Stony Brook, NY 11794, USA; Stony Brook Cancer Center, Stony Brook University Hospital, Stony Brook, NY 11794, USA; Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Department of Veterans Affairs, Northport VA Medical Center, Northport, NY 11768, USA. Electronic address: yusuf.hannun@stonybrookmedicine.edu.

Funding

Sphingolipids in Cancer Therapy and AngiogenesisP01CA097132 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI Daniel Canals · 2003 to 2026
$30.8M
Developing Novel Deep-Learning Based Methods for Deciphering Non-Coding Gene Regulatory CodeR01LM013722 · NLM · STATE UNIVERSITY NEW YORK STONY BROOK · PI RAMANA V DAVULURI · 2021 to 2026
$2.0M
BLRD VA I01 BX004621NCI NIH HHS P01 CA097132NLM NIH HHS R01 LM013722
6 · The paper itself

Abstract

Activating mutations in the epidermal growth factor receptor (EGFR) promote ligand-independent signaling; however, the mechanisms involved are poorly defined, and it is unknown whether this generates specific vulnerabilities. We previously observed robust expression of protein kinase Cα (PKCα) in lung adenocarcinoma (LUAD) with mutant EGFR (mEGFR), which, unlike the activation of PKCα, is independent of mEGFR activity. Here, we identify a critical role for PKCα in anchorage-independent growth and survival of lung cancer cells with mEGFR. Mechanistically, signaling pathways initiated by mEGFR show a high preference for ligand-independent phosphorylation on Y992, resulting in biased activation and dependence on phospholipase-Cγ and PKCα. Moreover, through bioinformatic approaches, we find that mEGFR LUAD demonstrates a transcriptomic profile most similar to lung basal cells, which exhibit elevated levels of PKCα, suggesting that mEGFR tumors arise in cell types with high intrinsic levels of PKCα. Taken together, these findings explain the dependence of mEGFR on PKCα.

Indexed as

Adenocarcinoma of LungErbB ReceptorsLung NeoplasmsMutationProtein Kinase C-alphaSignal TransductionCell Line, TumorHumansPhosphorylationEGFR protein, humanErbB ReceptorsPRKCA protein, humanProtein Kinase C-alphaAIGAISanchorage-independent growthanchorage-independent survivalcalcium signalingCP: CancerCSCDRNAligand-independent signalinglung basal cellslung cancermTORC1non-small cell lung cancerNSCLCPKCprotein kinase C

Identifiers

PMID39630579
PMCPMC12060138

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.